Study of Near-Infrared Imaging With Indocyanine Green for Detection of Sentinel Lymph Nodes in People With Vulvar Cancer
Key facts
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Where
- Basking Ridge, Commack, Harrison, Houston, Middletown, Montvale, New York, and Uniondale, United StatesSee the 8 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 22 people enrolled
- Started
- 6 Nov 2023
- Expected to end
- Nov 2027
- Type of study
- Interventional
- Treatments tested
- ICG guided sentinel lymph node biopsy
- Record updated
- 6 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- ≥18 years of age
- Newly diagnosed with vulvar cancer and scheduled to undergo SLN biopsy (patients with squamous cell carcinomas and melanomas will be included)
- Primary tumor ≤4 cm in size
- For patients with squamous cell carcinoma, >1 mm of invasion is required
Who cannot take part
- Clinically or radiographically enlarged inguinofemoral lymph nodes (if imaging is performed)
- Presence of distant metastases
- Absolute contraindication to radiocolloid Tc-99 or ICG
- Nonsquamous or nonmelanoma histologic subtype
Where in United States
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge, United States
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)Commack, United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison, United States
- Houston Methodist Cancer Center (Data Collection Only)Houston, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)Uniondale, United States
About the trial
What the trial wants to find out
The purpose of this study is to compare two types of imaging for sentinel lymph node (SLN) mapping in people with early-stage vulvar cancer. The researchers will compare indocyanine green near-infrared (ICG-NIR) imaging with lymphoscintigraphy. All participants in this study will be scheduled for standard surgical treatment at Memorial Sloan Kettering Cancer Center (MSK). This surgical treatment includes SLN mapping (with both lymphoscintigraphy and ICG-NIR imaging) and SLN biopsy.
The group in the trial
- patients undergoing preoperative lymphoscintigraphyTreatment being tested
Patients will undergo radiocolloid lymphoscintigraphy before their surgery; the surgeon will be blinded to the results of this procedure. The surgeon will subsequently inject ICG in accordance with the SLN protocol in the operating room and will identify and remove the SLN by use of near-infrared imaging guidance only.
Treatment: ICG guided sentinel lymph node biopsy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- VISION (Vulvar ICG SLN Detection) Study: Near-Infrared Imaging With Indocyanine Green Injection for the Detection of Sentinel Lymph Nodes in Vulvar Cancer
- Record updated
- 6 November 2026